Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Shares Acquired by Federated Hermes Inc.

Key Points

• Federated Hermes Inc. increased its stake in Zentalis Pharmaceuticals by 52.3% in Q1, owning over 752,000 shares valued at approximately $1.2 million.
• Zentalis stock has a current market cap of $99.29 million and a one-year range, with a low of $1.01 and a high of $5.44.
• Analysts maintain a "Moderate Buy" rating on Zentalis, with a price target averaging $8.37, and recent earnings beat consensus estimates by $0.19.

Federated Hermes Inc. raised its holdings in shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 52.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 752,517 shares of the company's stock after buying an additional 258,535 shares during the period. Federated Hermes Inc. owned about 1.05% of Zentalis Pharmaceuticals worth $1,197,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Deutsche Bank AG lifted its stake in shares of Zentalis Pharmaceuticals by 34.1% in the 4th quarter. Deutsche Bank AG now owns 42,804 shares of the company's stock valued at $130,000 after purchasing an additional 10,873 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Zentalis Pharmaceuticals by 17.0% during the first quarter. Wealth Enhancement Advisory Services LLC now owns 234,071 shares of the company's stock valued at $372,000 after purchasing an additional 33,958 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Zentalis Pharmaceuticals during the 4th quarter valued at $534,000. Millennium Management LLC lifted its stake in shares of Zentalis Pharmaceuticals by 8.1% in the 4th quarter. Millennium Management LLC now owns 957,563 shares of the company's stock worth $2,901,000 after purchasing an additional 71,477 shares during the period. Finally, Russell Investments Group Ltd. increased its stake in shares of Zentalis Pharmaceuticals by 169.2% in the 4th quarter. Russell Investments Group Ltd. now owns 60,021 shares of the company's stock worth $182,000 after purchasing an additional 37,726 shares in the last quarter.

Analyst Upgrades and Downgrades

Several research analysts have commented on ZNTL shares. Wedbush reissued a "neutral" rating and set a $4.00 price objective on shares of Zentalis Pharmaceuticals in a report on Thursday, May 15th. Wells Fargo & Company decreased their price objective on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday. Finally, HC Wainwright reissued a "buy" rating and set a $10.00 target price on shares of Zentalis Pharmaceuticals in a research note on Thursday, May 15th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, Zentalis Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Stock Performance

NASDAQ:ZNTL traded down $0.01 during mid-day trading on Friday, hitting $1.44. 497,237 shares of the company's stock traded hands, compared to its average volume of 1,251,326. Zentalis Pharmaceuticals, Inc. has a 1 year low of $1.01 and a 1 year high of $5.44. The firm's 50 day simple moving average is $1.37 and its 200 day simple moving average is $1.57. The company has a market cap of $103.61 million, a PE ratio of -0.64 and a beta of 1.71.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) EPS for the quarter, beating analysts' consensus estimates of ($0.56) by $0.19. On average, research analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.